Compare iShares Core MSCI EAFE ETF (IEFA) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Nuwellis Inc — how do they compare? iShares Core MSCI EAFE ETF trades at $95.89 (market cap $191.47B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: iShares Core MSCI EAFE ETF is far larger — about 87031.8× Nuwellis Inc's market cap, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 41 Days and Nuwellis Inc for 26 Days on average.
| IEFA | NUWE | |
|---|---|---|
Market Cap | $191.47B | $2.20M |
Volume | 11,673,895 | 121,544 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $146.65 |
52-Week Low | $85.06 | $0.68 |
Typical Hold Time | 41 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA (iShares Core MSCI EAFE ETF) trades at $96.20, down 1.08% with bearish technical signals from moving averages but neutral oscillators. The ETF provides exposure to developed markets outside North America with $196 billion in assets under management. Recent comparisons highlight its competitive expense ratio of 0.07% and higher dividend yield versus peers like Schwab's SCHF and State Street's SPDW.
The fund faces headwinds from international market volatility and currency risks, though its size and diversification offer stability. Near-term performance may be influenced by global economic conditions and investor rotation away from concentrated U.S. tech exposure. Key support sits at $95 with resistance at $97.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
